Literature DB >> 22977591

Enhancement of the efficacy of mitomycin C-mediated apoptosis in human colon cancer cells with RNAi-based thioredoxin reductase 1 deficiency.

Preeyaporn Koedrith1, Young Rok Seo.   

Abstract

Thioredoxin reductase 1 (Trr1) is an antioxidant and redox regulator that functions in governing the cellular redox state and survival against oxidative insults in mammals. However, this selenoprotein is also overexpressed in various forms of malignant cancers, leading to the hypothesis that Trr1 may be a potential target for cancer therapy. A quinone anti-cancer drug, mitomycin C (MMC), has been clinically used in the treatment of several types of tumors, including those of the colon. MMC exerts its activity via ROS induction and further results in DNA cross-linkage. To evaluate the significant role of Trr1 in MMC resistance in human colon cancer (RKO) cells, specific reduction in the expression of Trr1 was achieved using short-hairpin RNA (shRNA)-based interference. Our results showed that stable Trr1 shRNA knockdown manifested higher cellular susceptibility to MMC in comparison to that in wild-type cells. In addition, increased intracellular ROS accumulation appeared in the Trr1 shRNA knockdown cells compared to the RKO wild-type cells, in proportion to a relatively higher fraction of the DNA damage reporter protein phosphorylated histone 'γ-H2AX'. Notably, a neutral comet assay demonstrated that DNA double-strand breaks were highly induced in the Trr1-deficient cancer cells in the presence of MMC, presumably stimulating cancer cell death. Our results also revealed that MMC-induced apoptosis was associated with enhancement of oxidative damage to DNA. These results suggest that the specific knockdown of Trr1 expression via shRNA vector interference technology may be a potent molecular strategy by which to enhance the effectiveness of MMC-mediated killing in human colon cancer cells, through acceleration of double-strand DNA damage-oxidative stress as a trigger for apoptosis. This implies that Trr1 may be a prime target for enhancing the effectiveness of MMC chemotherapy in combination with specific RNA interference.

Entities:  

Year:  2011        PMID: 22977591      PMCID: PMC3440823          DOI: 10.3892/etm.2011.304

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

1.  The role of mitomycin antibiotics in the chemotherapy of solid tumors.

Authors:  A C Sartorelli
Journal:  Biochem Pharmacol       Date:  1986-01-01       Impact factor: 5.858

Review 2.  Severe side effects of the cytotoxic drug mitomycin-C.

Authors:  J Verweij; G Stoter
Journal:  Neth J Med       Date:  1987-02       Impact factor: 1.422

3.  Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells.

Authors:  Min-Hyuk Yoo; Xue-Ming Xu; Bradley A Carlson; Vadim N Gladyshev; Dolph L Hatfield
Journal:  J Biol Chem       Date:  2006-03-25       Impact factor: 5.157

Review 4.  Relationships between functionality and genetic toxicology of selected DNA-damaging agents.

Authors:  M Brendel; A Ruhland
Journal:  Mutat Res       Date:  1984-01       Impact factor: 2.433

5.  Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation.

Authors:  K Handa; S Sato
Journal:  Gan       Date:  1975-02

Review 6.  The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity.

Authors:  M Tomasz; Y Palom
Journal:  Pharmacol Ther       Date:  1997 Oct-Dec       Impact factor: 12.310

7.  Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas.

Authors:  Joon Hyuk Choi; Tae Nyeun Kim; Seongyong Kim; Suk-Hwan Baek; Jung Hye Kim; Seung Rock Lee; Jae-Ryong Kim
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

8.  Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy.

Authors:  Neelam Taneja; Mandel Davis; John S Choy; Michael A Beckett; Rachana Singh; Stephen J Kron; Ralph R Weichselbaum
Journal:  J Biol Chem       Date:  2003-10-15       Impact factor: 5.157

9.  High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy.

Authors:  Sofi E Eriksson; Stefanie Prast-Nielsen; Emilie Flaberg; Laszlo Szekely; Elias S J Arnér
Journal:  Free Radic Biol Med       Date:  2009-09-17       Impact factor: 7.376

10.  Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication.

Authors:  Min-Hyuk Yoo; Xue-Ming Xu; Bradley A Carlson; Andrew D Patterson; Vadim N Gladyshev; Dolph L Hatfield
Journal:  PLoS One       Date:  2007-10-31       Impact factor: 3.240

View more
  4 in total

Review 1.  Selenoproteins in colon cancer.

Authors:  Kristin M Peters; Bradley A Carlson; Vadim N Gladyshev; Petra A Tsuji
Journal:  Free Radic Biol Med       Date:  2018-05-22       Impact factor: 7.376

2.  Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard; Richard G Moore
Journal:  BMC Cancer       Date:  2012-04-13       Impact factor: 4.430

Review 3.  The Tumorigenic Roles of the Cellular REDOX Regulatory Systems.

Authors:  Stéphanie Anaís Castaldo; Joana Raquel Freitas; Nadine Vasconcelos Conchinha; Patrícia Alexandra Madureira
Journal:  Oxid Med Cell Longev       Date:  2015-11-22       Impact factor: 6.543

4.  Selenocysteine induces apoptosis in human glioma cells: evidence for TrxR1-targeted inhibition and signaling crosstalk.

Authors:  Cun-Dong Fan; Xiao-Yan Fu; Zong-Yong Zhang; Ming-Zhi Cao; Jing-Yi Sun; Ming-Feng Yang; Xiao-Ting Fu; Shi-Jun Zhao; Lu-Rong Shao; Hui-Fang Zhang; Xiao-Yi Yang; Bao-Liang Sun
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.